Ever Supreme Bio Technology Co Current Ratio

What does Ever Supreme Bio Technology Co do? Ever Supreme Bio Technology Co., Ltd. generates revenue through the research, development, and sale of stem cell products. The company's primary products include ADCV01, an autologous dendritic cell tumor vaccine currently in phase II clinical trials in Taiwan, and UMSC01, a human allogeneic umbilical cord stem cell product approved by the FDA for clinical phase I in the United States and undergoing similar trials in Taiwan for myocardial infarction treatment. UMSC01 is also being evaluated for acute ischemic stroke therapy in the United States under FDA phase I clinical trials. The firm targets medical institutions and healthcare providers in Taiwan and the United States for its stem cell therapies, focusing on cardiovascular and neurological conditions. The company's revenue streams are derived from the development and commercialization of its stem cell product pipeline, with ADCV01 and UMSC01 representing key assets in its portfolio. UMSC01's dual approval status in the U.S. and Taiwan positions it as a significant product for both markets. Ever Supreme Bio Technology plans to expand its offerings by developing mesenchymal stem cells for multiple sclerosis treatment, aiming to enter new therapeutic segments in the future. Ever Supreme Bio Technology Co is one of the most popular companies on Eulerpool.